Comparative Pharmacology
Head-to-head clinical analysis: MEPERIDINE AND ATROPINE SULFATE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERIDINE AND ATROPINE SULFATE versus QDOLO.
MEPERIDINE AND ATROPINE SULFATE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist primarily at mu-opioid receptors, producing analgesia; atropine is a competitive antagonist of muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretions.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
1-2 mL (meperidine 50 mg/mL + atropine 0.4 mg/mL) IM or IV push (over 2-3 minutes) every 3-4 hours as needed.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Meperidine: Terminal half-life 3-4 hours (normal renal function), prolonged in hepatic disease (up to 7-10 hours) and renal impairment (normeperidine accumulates). Atropine: Terminal half-life 2-4 hours.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Meperidine: Renal excretion of unchanged drug (~5-10%) and metabolites, primarily normeperidine (active), with <5% biliary/fecal. Atropine: Renal excretion (~30-50% unchanged), remainder as metabolites, minimal biliary/fecal.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist